Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Pancreatic cancer heterogeneity and response to Mek inhibition.

Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J.

Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5.

PMID:
28581516
2.

Achieving biodiversity benefits with offsets: Research gaps, challenges, and needs.

Gelcich S, Vargas C, Carreras MJ, Castilla JC, Donlan CJ.

Ambio. 2017 Mar;46(2):184-189. doi: 10.1007/s13280-016-0810-9. Epub 2016 Aug 16. Review.

3.

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.

Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J.

Clin Cancer Res. 2014 May 15;20(10):2793-804. doi: 10.1158/1078-0432.CCR-13-1837. Epub 2014 Mar 14.

4.

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J.

Clin Cancer Res. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. Epub 2013 Aug 27.

5.

A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.

Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E, Carreras MJ, Coronado C, Kahatt C, Soto Matos-Pita A, Fernandez Teruel C, Siguero M, Cullell-Young M, Tabernero J.

Cancer Chemother Pharmacol. 2013 May;71(5):1247-54. doi: 10.1007/s00280-013-2119-8. Epub 2013 Mar 2.

PMID:
23455428
6.

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S.

Ann Oncol. 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. Epub 2011 Aug 9.

PMID:
21828361
7.

Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D.

Clin Cancer Res. 2010 Apr 15;16(8):2375-82. doi: 10.1158/1078-0432.CCR-09-3275. Epub 2010 Apr 6.

8.

Dissociation between anti-infarct effect and anti-edema effect of ischemic preconditioning.

Sanz E, García Dorado D, Oliveras J, Barrabés JA, Gonzalez MA, Ruiz-Meana M, Solares J, Carreras MJ, García-Lafuente A, Desco M, et al.

Am J Physiol. 1995 Jan;268(1 Pt 2):H233-41.

PMID:
7840267
9.

Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion.

García-Dorado D, Oliveras J, Gili J, Sanz E, Pérez-Villa F, Barrabés J, Carreras MJ, Solares J, Soler-Soler J.

Cardiovasc Res. 1993 Aug;27(8):1462-9. Erratum in: Cardiovasc Res 1993 Oct;27(10):1889.

PMID:
8297415

Supplemental Content

Loading ...
Support Center